{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:38:43Z","timestamp":1771472323388,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00520-020-05880-5","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T08:03:41Z","timestamp":1609920221000},"page":"4081-4088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents"],"prefix":"10.1007","volume":"29","author":[{"given":"Go","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-1646","authenticated-orcid":false,"given":"Shunichiro","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"5880_CR1","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.3892\/ol.2019.10225","volume":"17","author":"Z Xu","year":"2019","unstructured":"Xu Z, Yang Q, Chen X, Zheng L, Zhang L, Yu Y, Chen M, You Q, Sun J (2019) Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: a population-based study. Oncol Lett 17:5590\u20135600. https:\/\/doi.org\/10.3892\/ol.2019.10225","journal-title":"Oncol Lett"},{"key":"5880_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3892\/mco.2014.410","volume":"3","author":"T Tamura","year":"2015","unstructured":"Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N (2015) Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 3:217\u2013221. https:\/\/doi.org\/10.3892\/mco.2014.410","journal-title":"Mol Clin Oncol"},{"key":"5880_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","volume":"89","author":"M Kuchuk","year":"2015","unstructured":"Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P (2015) The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer 89:197\u2013202. https:\/\/doi.org\/10.1016\/j.lungcan.2015.04.007","journal-title":"Lung Cancer"},{"key":"5880_CR4","doi-asserted-by":"publisher","first-page":"18670","DOI":"10.1038\/srep18670","volume":"5","author":"D Santini","year":"2015","unstructured":"Santini D, Barni S, Intagliata S, Falcone A, Ferra\u00f9 F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collov\u00e0 E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G (2015) Natural history of non-small-cell lung cancer with bone metastases. Sci Rep 5:18670\u201318670. https:\/\/doi.org\/10.1038\/srep18670","journal-title":"Sci Rep"},{"key":"5880_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584. https:\/\/doi.org\/10.1093\/annonc\/mdi122","journal-title":"Ann Oncol"},{"key":"5880_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3892\/ol.2018.9680","volume":"17","author":"H Kunikane","year":"2019","unstructured":"Kunikane H, Yokota I, Katakami N, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Ohashi Y, Eguchi K (2019) Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13). Oncol Lett 17:1320\u20131326. https:\/\/doi.org\/10.3892\/ol.2018.9680","journal-title":"Oncol Lett"},{"key":"5880_CR7","doi-asserted-by":"publisher","first-page":"e9327","DOI":"10.1097\/MD.0000000000009327","volume":"96","author":"P Kong","year":"2017","unstructured":"Kong P, Yan J, Liu D, Ji Y, Wang Y, Zhuang J, Wang J, Hu X, Yue X (2017) Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - a retrospective analysis. Medicine (Baltimore) 96:e9327\u2013e9327. https:\/\/doi.org\/10.1097\/MD.0000000000009327","journal-title":"Medicine (Baltimore)"},{"key":"5880_CR8","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.jbo.2018.10.004","volume":"15","author":"S D\u2019Oronzo","year":"2018","unstructured":"D\u2019Oronzo S, Coleman R, Brown J, Silvestris F (2018) Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol 15:100205. https:\/\/doi.org\/10.1016\/j.jbo.2018.10.004","journal-title":"J Bone Oncol"},{"key":"5880_CR9","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1007\/s00520-019-4635-5","volume":"27","author":"A Bongiovanni","year":"2019","unstructured":"Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T (2019) Ten-year experience of the multidisciplinary Osteoncology Center. Support Care Cancer 27:3395\u20133402","journal-title":"Support Care Cancer"},{"key":"5880_CR10","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621. https:\/\/doi.org\/10.1002\/cncr.20308","journal-title":"Cancer"},{"key":"5880_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304","journal-title":"J Clin Oncol"},{"key":"5880_CR12","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275\/","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192\u2013iv237. https:\/\/doi.org\/10.1093\/annonc\/mdy275\/","journal-title":"Ann Oncol"},{"key":"5880_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C (2017) Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline Practical Radiation. Oncology 7:4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001","journal-title":"Oncology"},{"key":"5880_CR14","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2020) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer Version 3.2020-February 11, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Acceced 3 March 2020"},{"key":"5880_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3892\/mco.2019.1903","volume":"11","author":"Y Nakahara","year":"2019","unstructured":"Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H (2019) Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Mol Clin Oncol 11:349\u2013353. https:\/\/doi.org\/10.3892\/mco.2019.1903","journal-title":"Mol Clin Oncol"},{"key":"5880_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2008.10.026","volume":"65","author":"I Sekine","year":"2009","unstructured":"Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65:219\u2013222. https:\/\/doi.org\/10.1016\/j.lungcan.2008.10.026","journal-title":"Lung Cancer"},{"key":"5880_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2010.04.003","volume":"71","author":"J-M Sun","year":"2011","unstructured":"Sun J-M, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn M-J, Ahn YC, Park K (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71:89\u201393. https:\/\/doi.org\/10.1016\/j.lungcan.2010.04.003","journal-title":"Lung Cancer"},{"key":"5880_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","volume":"139","author":"A Hussain","year":"2019","unstructured":"Hussain A, Lee RJ, Graff JN, Halabi S (2019) The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Crit Rev Oncol Hematol 139:108\u2013116. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.04.020","journal-title":"Crit Rev Oncol Hematol"},{"key":"5880_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"5880_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","volume":"24","author":"H Akamatsu","year":"2019","unstructured":"Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Immamura CK, Katsuya Y, Matsui R, Mineishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N (2019) The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24:731\u2013770. https:\/\/doi.org\/10.1007\/s10147-019-01431-z","journal-title":"Int J Clin Oncol"},{"key":"5880_CR21","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","volume":"27","author":"A Inoue","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K, North East Japan Gefitinib Study G (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394\u20131400. https:\/\/doi.org\/10.1200\/JCO.2008.18.7658","journal-title":"J Clin Oncol"},{"key":"5880_CR22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","volume":"12","author":"E Iwama","year":"2017","unstructured":"Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I (2017) Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol 12:1161\u20131166. https:\/\/doi.org\/10.1016\/j.jtho.2017.02.012","journal-title":"J Thorac Oncol"},{"key":"5880_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00774-009-0080-8","volume":"27","author":"N Yoshimura","year":"2009","unstructured":"Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis\/osteoporosis against disability study. J Bone Miner Metab 27:620\u2013628. https:\/\/doi.org\/10.1007\/s00774-009-0080-8","journal-title":"J Bone Miner Metab"},{"key":"5880_CR24","doi-asserted-by":"publisher","first-page":"e8294","DOI":"10.1097\/MD.0000000000008294","volume":"96","author":"L Tian","year":"2017","unstructured":"Tian L, Yang R, Wei L, Liu J, Yang Y, Shao F, Ma W, Li T, Wang Y, Guo T (2017) Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China. Medicine (Baltimore) 96:e8294\u2013e8294. https:\/\/doi.org\/10.1097\/MD.0000000000008294","journal-title":"Medicine (Baltimore)"},{"key":"5880_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/02841860310017973","volume":"43","author":"R Moore","year":"2004","unstructured":"Moore R, Doherty D, Chamberlain R, Khuri F (2004) Sex differences in survival in non-small cell lung cancer patients 1974-1998. Acta Oncol 43:57\u201364. https:\/\/doi.org\/10.1080\/02841860310017973","journal-title":"Acta Oncol"},{"key":"5880_CR26","doi-asserted-by":"publisher","first-page":"e0219206","DOI":"10.1371\/journal.pone.0219206","volume":"14","author":"C Radkiewicz","year":"2019","unstructured":"Radkiewicz C, Dickman PW, Johansson ALV, Wagenius G, Edgren G, Lambe M (2019) Sex and survival in non-small cell lung cancer: a nationwide cohort study. PLoS One 14:e0219206. https:\/\/doi.org\/10.1371\/journal.pone.0219206","journal-title":"PLoS One"},{"key":"5880_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00432-017-2350-5","volume":"143","author":"H Udagawa","year":"2017","unstructured":"Udagawa H, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Goto K (2017) Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases. J Cancer Res Clin Oncol 143:1075\u20131082. https:\/\/doi.org\/10.1007\/s00432-017-2350-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"5880_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"S Peters","year":"2020","unstructured":"Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Granados A, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Ragablio M, O\u2019Brien M, Stahel RA (2020) A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. J Thorac Oncol 15:1647\u20131656. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.011","journal-title":"J Thorac Oncol"},{"key":"5880_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ejrad.2011.01.126","volume":"81","author":"X Qu","year":"2012","unstructured":"Qu X, Huang X, Yan W, Wu L, Dai K (2012) A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 81:1007\u20131015. https:\/\/doi.org\/10.1016\/j.ejrad.2011.01.126","journal-title":"Eur J Radiol"},{"key":"5880_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1248\/bpb.b18-00997","volume":"42","author":"Y Suga","year":"2019","unstructured":"Suga Y, Uchida M, Suzuki S, Sugawara H, Torigoe K, Futamura A, Uesawa Y, Nakagawa T, Takase H (2019) Current status of adverse events related with opioid analgesics in Japan: assessment based on Japanese Adverse Drug Event Report Database. Biol Pharm Bull 42:801\u2013806. https:\/\/doi.org\/10.1248\/bpb.b18-00997","journal-title":"Biol Pharm Bull"},{"key":"5880_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","volume":"25","author":"E Chow","year":"2007","unstructured":"Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423\u20131436. https:\/\/doi.org\/10.1200\/JCO.2006.09.5281","journal-title":"J Clin Oncol"},{"key":"5880_CR32","doi-asserted-by":"publisher","first-page":"viii497","DOI":"10.1093\/annonc\/mdy292.007","volume":"29","author":"G Middleton","year":"2018","unstructured":"Middleton G, Brock K, Summers Y, Connibear J, Shah R, Ottensmeier C, Shaw P, Ming-Lee S, Popat S, Barrie C, Barone G, Mant R, Savage JS, Billingham L (2018) Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial. Ann Oncol 29:viii497. https:\/\/doi.org\/10.1093\/annonc\/mdy292.007","journal-title":"Ann Oncol"},{"key":"5880_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","volume":"127","author":"E Felip","year":"2020","unstructured":"Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Garcia MA, Isla D, Jassem J, Appel W, Milanowski J, Van Meerbeeck JP, Wolf J, Li A, Acevedo A, Popat S (2020) CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 127:160\u2013172. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.019","journal-title":"Eur J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05880-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05880-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05880-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T06:22:48Z","timestamp":1622182968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05880-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5880"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05880-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Saito reports personal fees from AstraZeneca, during the conduct of the study, personal fees from Chugai Pharmaceutical, and personal fees from Ono Pharmaceutical, outside the submitted work; Dr. Iwasawa reports personal fees from Daiichi Sankyo Company, Limited, personal fees from AstraZeneca K.K., personal fees from Bristol-Myers Squibb K.K., personal fees from MSD K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., during the conduct of the study, and personal fees from Chugai Pharmaceutical Co., Ltd., outside the submitted work; Dr. Takiguchi reports grants and personal fees from Novartis, grants from Daiichi Sankyo, personal fees from AstraZeneca, during the conduct of the study, grants and personal fees from Eli Lilly, grants and personal fees from Chugai Pharmaceutical Co., grants and personal fees from MSD, grants from Takeda, grants and personal fees from Taiho Pharmaceutical Co., grants from Kyowa-Hakko Kirin, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical Co., and grants and personal fees from Bristol Meyers Squib, outside the submitted work; Dr. Ebata, Dr. Ishiwata, Dr. Yoshino, and Dr. Tatsumi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board of the Chiba University Hospital approved the study protocol (approval no.2634).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Given the retrospective nature and the anonymous design of our study, written informed consent was not obtained from patients, who were however provided with the opportunity to opt out of their confidential patient information being used for research using our institutional website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We provided all patients with the opportunity to opt out of their confidential patient information being used for research using our institutional website.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}